Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors

Table 1

Patient characteristics in the MAO-B inhibitor and dopamine agonist group.

	MAO-B inhibitors (n = 850)	Dopamine agonists (n = 22108)
Proportion of men	58.12	38.23
Age distribution	9.41, 35.53, 39.06, 16	24.07, 30.03, 26.66, 19.24
Proportion with drugs for diabetes (none)	6.12	9.98
Proportion with drugs for hypothyroidism (none)	8.71	12.76
Proportion with drugs for hypertension (none)	11.53	15
Proportion with drugs for atrial fibrillation (none)	42.12	39.37
Proportion with first prescription for the MAO-B inhibitor/dopamine agonist from the specialist	3.88	1
Days observed	712, 362, 1, 3789	1733, 1623.5, 1, 3836
Proportion with levodopa prescription dispensed	58.59	6.39
Days until levodopa prescription dispensed	352, 187, 1, 2081	621, 315, 1, 3665

Age groups, 50–59, 60–69, 70–79, and 80+. Mean, median, min, and max.